AtriCure Reports Q1 2026 Earnings with Strong Revenue Growth
AtriCure (ATRC) reported Q1 2026 earnings with worldwide revenue of $141.2 million, a 14.3% increase year-over-year. The growth was driven by strong performance in key product lines such as open ablation and appendage management devices. U.S. revenue rose 14.9% to $116.2 million, while the pain management franchise saw a 29.5% increase in the U.S.
Tickers: $ATRC
Topics: financial performance market growth product adoption revenue